Sector News

Perrigo’s fate is in shareholders’ hands, Mylan chairman says. Or is it?

September 8, 2015
Life sciences

With the go-ahead from its own shareholders, Mylan is now pushing full steam ahead to acquire Perrigo–and as Chairman Robert Coury wrote in a Tuesday letter to its Irish target’s CEO, “you and your board are now unable to stop the combination.”

Mylan, whose investors voted recently to push forward with the hostile tie-up, will next week launch its formal offer to acquire Perrigo shares, paying $75 in cash and 2.3 Mylan shares for each. And at that point, the fate of the OTC specialist will rest in the hands of its shareholders, who will have to decide whether to take Mylan up on its offer.

“At this point, Perrigo’s management has no role to play in the process,” Coury stressed in the letter to Perrigo chief Joseph Papa.

Coury, for one, is confident Perrigo’s investors will see things the way Mylan does. Aside from Mylan’s offer posing a “very attractive” option, it’s also been protecting Perrigo’s stock from “the recent sell-off in the markets,” he wrote. So if the transaction doesn’t go through, he figures, Perrigo shareholders will “potentially experience an approximate $30 per share drop in the value of their portfolio, and lose the opportunity to receive $75 per share in cash.”

Papa, on the other hand, has expressed confidence more than once that Perrigo’s shareholders will reject the offer, and some analysts think that’s the way to go. Bernstein analyst Ronny Gal, for one, wrote in a Tuesday note to clients that the deal has “weak financial rationale” with “stretched” cost-cutting potential and revenue synergies that are “unlikely to materialize.”

But that doesn’t mean Perrigo shareholders won’t take it up. “The acquisition may still go through simply due to the ability of near-term oriented investors to dominate the count,” he wrote.

Perrigo’s move, if it wants to prevent that from happening? Make its own offer, Gal suggests. “If Perrigo can offer a reasonable value enhancing alternative, it will likely convince enough investors (including some hedge funds and dual-stock holders) not to tender in their shares,” he wrote. “We think it behooves Perrigo management to do just that.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”